Kolon Pharm

Kolon Pharm is a South Korean pharmaceutical company established in 1958 and a subsidiary of the Kolon Group. The company focuses on the manufacturing, marketing, and sales of prescription drugs, over-the-counter (OTC) medicines, and health supplements, with core therapeutic strengths in respiratory and dermatology areas. In August 2026, Kolon Pharm spun off its new drug R&D unit to launch TonX BIO, an independent entity focused on translational research and oncology drug development. Despite the spin-off, Kolon Pharm continues to engage in strategic R&D collaborations, such as its partnership with Pharos iBio to develop PHI-701, a next-generation EGFR inhibitor for non-small cell lung cancer, and its collaboration with Aptamer Sciences on AST-203, a TROP2-targeting aptamer-drug conjugate for pancreatic cancer.